摘要
克罗恩病(CD)与遗传、免疫、肠菌等多因素相互作用有关,近年来,随着对CD病理生理学状况了解的加深,许多有效的生物学治疗方法已经应用于CD治疗中。肿瘤坏死因子(TNF)是一种重要的免疫介质和前炎症因子,它在CD发病中的作用日益受到重视,全文概述几种有效的抗TNF生物制剂在CD中的应用。目前只有infliximab获美国FDA批准用于CD的治疗,其余治疗策略需更多资料证实其疗效。
Crohn disease （CD） is related with a complex interplay among genetic, immune and microbial factors. In recent years, many effective biological treatments have been used in CD. Tumor necrosis factor （TNF） is a significant immune mediator and proinflammatory factor, its role in the mechanism of CD has been realized more and more. In the article we review the application of several effective anti-TNF biologic agents in CD. Infliximab is the only US Food and Drug Administration （FDA） approved biologic agent for the treatment of CD by far, other treatments need more data to confirm their effect.
出处
《国际消化病杂志》
CAS
2006年第2期84-86,共3页
International Journal of Digestive Diseases
